{"id":"oxymetazoline-hcl-cream-1-0","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Skin burning or stinging"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxymetazoline binds to alpha-1 adrenergic receptors on vascular smooth muscle cells, triggering vasoconstriction. This reduces blood flow to the affected area and decreases the appearance of erythema (redness). The cream formulation allows topical application directly to areas of facial redness, providing localized therapeutic effect without systemic absorption.","oneSentence":"Oxymetazoline is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the skin, reducing redness and flushing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:22.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Persistent facial erythema associated with rosacea"}]},"trialDetails":[{"nctId":"NCT02132117","phase":"PHASE3","title":"Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06","conditions":"Erythema, Rosacea","enrollment":445},{"nctId":"NCT02095158","phase":"PHASE3","title":"A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04","conditions":"Erythema, Rosacea","enrollment":440},{"nctId":"NCT03380390","phase":"PHASE4","title":"Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-12-04","conditions":"Rosacea","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AGN-199201","Rhofade"],"phase":"marketed","status":"active","brandName":"Oxymetazoline HCL Cream 1.0%","genericName":"Oxymetazoline HCL Cream 1.0%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxymetazoline is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the skin, reducing redness and flushing. Used for Persistent facial erythema associated with rosacea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}